MTC
PTGX icon

Matrix Trust Company’s Protagonist Therapeutics PTGX Stock Holding History

Matrix Trust Company’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-143
Closed -$12K – 231
2025
Q4 		$12K Buy
+143
New +$11.7K ﹤0.01% 202

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Matrix Trust Company's PTGX Position: Q1 2026 in Review

Matrix Trust Company sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 143 shares — an estimated $12K sold.

Matrix Trust Company first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $12K in Q4 2025. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Matrix Trust Company reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Matrix Trust Company sold 143 Protagonist Therapeutics shares in Q1 2026, an estimated $12K.
  • Matrix Trust Company first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
  • Matrix Trust Company's Protagonist Therapeutics position peaked at $12K in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Matrix Trust Company's 13F filing for Q1 2026, filed 10 Apr 2026.